We treated cSCC cells with THZ1, a covalent inhibitor of CDK7, and JQ1, a specific inhibitor of BRD4, which both have been shown to selectively target SE-driven transcriptional programs in cancer [32,33]. The gene discussed is BRD4; the disease is cancer.